Alzheimer’s Disease is the most common cause of dementia. Dementia describing a specific set of symptoms such as memory loss, difficulties with problem-solving, language or simply thinking. As the disease progresses, proteins build up in the brain to form structures called ‘plaques’. Eventually there is a break between the nerve cells resulting the death of the cells and a loss of brain tissue. ending in a lack of motor skills. Although progression can vary, typically after diagnosis life expectancy is around three to nine years. Fewer than 3% of people live more than fourteen years.
Management
Medications, psychological intervention and care-giving are all available to AD patients. there are currently 5 different medications on offer for AD each have different results and side affects.
FDA clearance of the first Alzheimer's blood test marks a significant step toward earlier, more straightforward diagnosis—potentially improving care for adults with memory concerns.
An experimental Alzheimer's drug called donanemab, developed by Eli Lilly, has demonstrated a slowdown in progression of disease at early stages, according to trial data.
Abbas Kanani, Superintendent Pharmacist at Chemist Click Online Pharmacy, walks us through treatments for Alzheimer’s disease, researching the causes, diagnosis, prevention, and cure.
Efforts to prevent or treat Alzheimer’s Disease (AD) by targeting Amyloid beta (Aβ) assemblies should be continued, but the strategies should be altered dramatically.
In this interview, Abbas Kanani, MRPharmS, Superintendent Pharmacist at Chemist Click, tells us about amyloidosis, a group of rare diseases in which abnormal proteins deposit as amyloid in tissues and organs.
Researchers are developing a new Alzheimer's disease detection sensor that can be used in the early stages of Alzheimers and a number of other diseases.
Dr. Gerardo Fernandez, CSO ViewMind Inc, investigates how early is too early for the detection of Alzheimer’s disease and how soon in the disease’s trajectory detection can make a meaningful difference in a patient’s prognosis.
After decades of failure for Alzheimer’s researchers, Lecanemab could open the door to a new ear of drugs to treat Alzheimer’s disease – the world's most common form of dementia.
COVID-19 activates the same inflammatory response in the brain as Parkinson’s disease – increasing the risk of future potential neurodegenerative conditions.
Alzheimers drugs have been shown able to target insulin receptors located in cerebral microvessels, massively expanding the future of drug production and testing
Is better diagnosis the key to unlocking life-changing dementia treatments? Dr Susan Mitchell, Head of Policy at Alzheimer’s Research UK provides the answer.
